Drug intelligence / Profile preview

APOE4 correction program

Development stage: Preclinical
Lead developer: GeneLancet Biosciences
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies

Overview

GeneLancet Biosciences is developing a gene editing therapy for Alzheimer's Disease using its proprietary DuoSTAR (dual segNA-guided CRISPR-polymerase editor) platform. The therapy is designed to correct the APOE4 allele—the strongest genetic risk factor for late-onset Alzheimer's—by converting it into the more benign APOE3 variant. This approach aims to provide a curative treatment by directly modifying the underlying genetic risk factor at the genomic level. The program is currently in the IND-enabling stage of development.

Other names: Alzheimer's Disease ProgramAPOE4 -> APOE3 editingDuoSTAR APOE4 program

Targets

APOE (Apolipoprotein E)

Beyond the preview

Go deeper on APOE4 correction program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APOE4 correction program.

Explore the full profile